The most commonly reported adverse reactions (≥ 10%) in the Gamifant® (emapalumab-lzsg) pivotal trial included:
|Adverse reactions||Gamifant (N=34)||Adverse reactions||Gamifant (N=34)|
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.3,6
is given as an intravenous infusion twice a week until hematopoietic stem cell transplantation (HSCT) is performed.1
can be ordered through our specialty pharmacy or one of our specialty distributors.